Several large clinical trials have shown the renal and cardioprotective effects of SGLT2 inhibitors in diabetes patients, and some of those effects are independent of the improvement of the blood glucose level (Zinman et al., 2015; Wanner et al., 2016; Perkovic et al., 2019). This evidence concerns the gene SLC5A2 and diabetes mellitus.